Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Tazarotene
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Bioavailability Study of DFD-03 Compared to Tazorac® in Patients With Moderate Acne Vulgaris
Details : Tazarotene is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Acne Vulgaris.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 26, 2018
Lead Product(s) : Tazarotene
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : PPC-06
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study to Assess the Efficacy and Safety of PPC-06 (Tepilamide Fumarate)
Details : PPC-06 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Psoriasis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 05, 2018
Lead Product(s) : PPC-06
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Minocycline Hydrochloride
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Minocycline is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Rosacea.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 14, 2017
Lead Product(s) : Minocycline Hydrochloride
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : DFD-03
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : DFD-03 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Acne Vulgaris.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
November 14, 2017
Lead Product(s) : DFD-03
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : DFD-04
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study to Assess the Efficacy, Safety and Tolerability of DFD-04
Details : DFD-04 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Rosacea.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
July 11, 2016
Lead Product(s) : DFD-04
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : XP23829
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : XENOPORT INC
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : XP23829 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Psoriasis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 24, 2014
Lead Product(s) : XP23829
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : XENOPORT INC
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Abametapir
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Abametapir is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Lice Infestations.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 27, 2014
Lead Product(s) : Abametapir
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Abametapir
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Ha44 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Lice Infestations.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 12, 2013
Lead Product(s) : Abametapir
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Benzyl Alcohol
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Accelovance | Target Health Inc.
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety and PK Study of Ha44 Gel Under Maximal Use Conditions for Treatment of Head Lice Infestation
Details : Benzyl Alcohol is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Lice Infestations.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 25, 2013
Lead Product(s) : Benzyl Alcohol
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Accelovance | Target Health Inc.
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Abametapir
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Ha44 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Lice Infestations.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 18, 2011
Lead Product(s) : Abametapir
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
